Adma Biologics, Inc.
ADMA
Biological Products, (No Diagnostic Substances)
Mkt Cap
$2.177BPE
-597.28Debt
-Cash
$45.33MEV
-FCF
$16.13MP/E Ratio
-597.28Debt
-Cash
$45.33MEV
-FCF
$16.13MCharts data: {"Earnings":[{"time":"2014-12-30","value":-16813163},{"time":"2015-12-30","value":-17969930},{"time":"2016-12-30","value":-19515151},{"time":"2017-12-30","value":-43758975},{"time":"2018-12-30","value":-65743445},{"time":"2019-12-30","value":-48279317},{"time":"2020-12-30","value":-75748548},{"time":"2021-12-30","value":-71647618},{"time":"2022-12-30","value":-65903950},{"time":"2023-12-30","value":-28239000}],"Sales":[{"time":"2014-12-30","value":5915545},{"time":"2015-12-30","value":7177633},{"time":"2016-12-30","value":10661037},{"time":"2017-12-30","value":22760560},{"time":"2018-12-30","value":16985290},{"time":"2019-12-30","value":29349083},{"time":"2020-12-30","value":42219783},{"time":"2021-12-30","value":80942625},{"time":"2022-12-30","value":154079692},{"time":"2023-12-30","value":258215000}],"Net Margins":[{"time":"2014-12-30","value":-2.842200169215178},{"time":"2015-12-30","value":-2.5036011175271846},{"time":"2016-12-30","value":-1.8305115159060044},{"time":"2017-12-30","value":-1.922579013873121},{"time":"2018-12-30","value":-3.8706106872476127},{"time":"2019-12-30","value":-1.6450025712898764},{"time":"2020-12-30","value":-1.7941482077252742},{"time":"2021-12-30","value":-0.8851654860464434},{"time":"2022-12-30","value":-0.42772638719968364},{"time":"2023-12-30","value":-0.10936235307786148}],"Assets":[{"time":"2014-12-30","value":27227497},{"time":"2015-12-30","value":23714517},{"time":"2016-12-30","value":23685085},{"time":"2017-12-30","value":108018833},{"time":"2018-12-30","value":88876521},{"time":"2019-12-30","value":127090725},{"time":"2020-12-30","value":207673394},{"time":"2021-12-30","value":276252724},{"time":"2022-12-30","value":348461881},{"time":"2023-12-30","value":329182000}],"Stockholders Equity":[{"time":"2014-12-30","value":6008650},{"time":"2015-12-30","value":820974},{"time":"2016-12-30","value":-4457262},{"time":"2017-12-30","value":40332757},{"time":"2018-12-30","value":19770438},{"time":"2019-12-30","value":26193149},{"time":"2020-12-30","value":88249426},{"time":"2021-12-30","value":141172566},{"time":"2022-12-30","value":151974215},{"time":"2023-12-30","value":135206000}],"ROE":[{"time":"2014-12-30","value":-2.7981598195934194},{"time":"2015-12-30","value":-21.888549454672134},{"time":"2016-12-30","value":4.37828222796865},{"time":"2017-12-30","value":-1.084948767573712},{"time":"2018-12-30","value":-3.3253408447501265},{"time":"2019-12-30","value":-1.8432039996412803},{"time":"2020-12-30","value":-0.8583460701489435},{"time":"2021-12-30","value":-0.5075179975123495},{"time":"2022-12-30","value":-0.43365218237843833},{"time":"2023-12-30","value":-0.20885907430143633}],"ROA":[{"time":"2014-12-30","value":-0.5883219085470839},{"time":"2015-12-30","value":-0.65419030039701},{"time":"2016-12-30","value":-0.7317007728703528},{"time":"2017-12-30","value":-0.3639179845610811},{"time":"2018-12-30","value":-0.6783450040759359},{"time":"2019-12-30","value":-0.32594295925214056},{"time":"2020-12-30","value":-0.3125815770122195},{"time":"2021-12-30","value":-0.2113055761216675},{"time":"2022-12-30","value":-0.11296810970265066},{"time":"2023-12-30","value":0.0657144072276127}]}
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Sector
DCF
Discounted Cash Flow Valuation of Adma Biologics, Inc.
Value
Growth
%
%
Discount
%
%
Multiple
| g\r | +10% | +11% | +12% | +13% | +14% |
|---|---|---|---|---|---|
| 0% | 10 | 9 | 8 | 8 | 7 |
| +1% | 11 | 10 | 9 | 8 | 8 |
| +2% | 13 | 11 | 10 | 9 | 8 |
| +3% | 14 | 13 | 11 | 10 | 9 |
| +4% | 17 | 14 | 12 | 11 | 10 |
| Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF | $16.13M | $20.97M | $26.68M | $33.2M | $40.39M | $48.02M | $55.76M | $63.2M | $69.87M | $75.3M | $79.06M | $790.6M |
| DCF | $18.23M | $20.17M | $21.83M | $23.1M | $23.88M | $24.11M | $23.76M | $22.84M | $21.4M | $19.54M | $195.4M | |
| Value | $414.3M | |||||||||||
In the chart Earnings are multiplied by this value.
Earnings Growth -
Earnings Stability -
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -250% | -180% | -190% | -390% | -160% | -180% | -89% | -43% | -11% | -1.3% |
| ROA | -65% | -73% | -36% | -68% | -33% | -31% | -21% | -11% | 6.6% | 13% |
| ROE | -2.2K% | 440% | -110% | -330% | -180% | -86% | -51% | -43% | -21% | -2.4% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -145.53%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is +66.76%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -26.26%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is +12.74%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -119.62%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is +57.61%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | 0.00 | -0.43 | -0.07 | -0.46 | -0.91 | - | - | - | - | - |
| Debt Equity | 0.00 | -1.77 | 0.07 | 1.52 | 2.77 | - | - | - | - | - |
| MIN | ||||||||||
| Graham Stability | - | - | - | - | - | - | - | - | - | - |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -0.44.
What is the Graham’s Stability?
Graham’s Stability measure stands at -.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 58% | 72% | 83% | 68% | 5.6% |
| Net Income | - | - | - | - | - |
| Stockholders Equity | - | 47% | 15% | -11% | 14% |
| FCF | - | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +72.34%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is +5.6%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is -15.55%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +46.89%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is +13.75%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is -.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.